Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
I agree to receive
the R3i newsletter

RECENT PUBLICATIONS ON RESIDUAL RISK

2018

News flash: REDUCE-IT meets primary endpoint

Topline results of the REDUCE-IT trial show that high doses (4-g daily) of eicosapentaenoic acid (EPA) led to a 25% relative reduction in major adverse cardiovascular events (a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina requiring hospitalization) over a median follow-up of 4.9 years. Results will be reported at the American Heart Association Scientific Sessions this November.
REDUCE-IT™ Cardiovascular Outcomes Study of Vascepa® (icosapent ethyl) Capsules Met Primary Endpoint